These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7886270)

  • 1. Persistent GHRH-induced PRL secretion in Cushing's syndrome, obesity and exogenous hypercortisolism.
    Cordido F; Peino R; Martínez-Ramonde T
    Rev Esp Fisiol; 1994 Sep; 50(3):139-43. PubMed ID: 7886270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
    Panminerva Med; 1998 Mar; 40(1):13-7. PubMed ID: 9573747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing's syndrome.
    Leal-Cerro A; Pumar A; Garcia-Garcia E; Dieguez C; Casanueva FF
    Clin Endocrinol (Oxf); 1994 Nov; 41(5):649-54. PubMed ID: 7828354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marked GH secretion after ghrelin alone or combined with GH-releasing hormone (GHRH) in obese patients.
    Alvarez-Castro P; Isidro ML; Garcia-Buela J; Leal-Cerro A; Broglio F; Tassone F; Ghigo E; Dieguez C; Casanueva FF; Cordido F
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):250-5. PubMed ID: 15272922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
    Mukherjee A; Murray RD; Teasdale GM; Shalet SM
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
    Minerva Endocrinol; 1999; 24(3-4):107-11. PubMed ID: 10953725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing's syndrome.
    Leal-Cerro A; Soto A; Martínez MA; Alvarez P; Isidro L; Casanueva FF; Dieguez C; Cordido F
    Clin Endocrinol (Oxf); 2002 Dec; 57(6):745-9. PubMed ID: 12460324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone releasing hormone priming increases growth hormone secretion in patients with Cushing's syndrome.
    Leal-Cerro A; Pumar A; Villamil F; Astorga R; Dieguez C; Casanueva FF
    Clin Endocrinol (Oxf); 1993 Apr; 38(4):399-403. PubMed ID: 8319372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of sumatriptan on growth hormone releasing hormone-stimulated growth hormone secretion in acromegaly.
    Cuttica CM; Sessarego P; Ponzani P; Falivene MR; Valenti S; De Martini D; Giusti M
    Recenti Prog Med; 1997 Jun; 88(6):264-8. PubMed ID: 9233053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone secretion in primary adrenal Cushing's syndrome is disorderly and inversely correlated with body mass index.
    van Aken MO; Pereira AM; Frölich M; Romijn JA; Pijl H; Veldhuis JD; Roelfsema F
    Am J Physiol Endocrinol Metab; 2005 Jan; 288(1):E63-70. PubMed ID: 15328071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of GH reserve in patients with adrenal incidentalomas and biochemical evidence of subclinical autonomous glucocorticoid hypersecretion.
    Tzanela M; Zianni D; Stylianidou Ch; Karavitaki N; Tsagarakis S; Thalassinos NC
    Clin Endocrinol (Oxf); 2005 May; 62(5):597-602. PubMed ID: 15853831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of alprazolam, a benzodiazepine, on the ACTH-, GH- and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease.
    Grottoli S; Arvat E; Gauna C; Maccagno B; Ramunni J; Giordano R; Maccario M; Deghenghi R; Ghigo E
    Pituitary; 1999 Nov; 2(3):197-204. PubMed ID: 11081154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profound amplification of secretory-burst mass and anomalous regularity of ACTH secretory process in patients with Nelson's syndrome compared with Cushing's disease.
    van Aken MO; Pereira AM; van den Berg G; Romijn JA; Veldhuis JD; Roelfsema F
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):765-72. PubMed ID: 15163342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone and prolactin are secreted more irregularly in patients with Cushing's disease.
    Veldman RG; Frölich M; Pincus SM; Veldhuis JD; Roelfsema F
    Clin Endocrinol (Oxf); 2000 May; 52(5):625-32. PubMed ID: 10792343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pituitary function in patients with newly diagnosed untreated systemic lupus erythematosus.
    Köller MD; Templ E; Riedl M; Clodi M; Wagner O; Smolen JS; Luger A
    Ann Rheum Dis; 2004 Dec; 63(12):1677-80. PubMed ID: 15082470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary restriction in patients with Cushing's syndrome.
    Leal-Cerro A; Venegas E; Garcia-Pesquera F; Jimenez LM; Astorga R; Casanueva FF; Dieguez C
    Clin Endocrinol (Oxf); 1998 Jan; 48(1):117-21. PubMed ID: 9509077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of leptin levels in plasma and their reliance on other hormonal factors affecting tissue fat levels in people with various levels of endogenous cotisol].
    Robaczyk MG
    Ann Acad Med Stetin; 2002; 48():283-300. PubMed ID: 14601484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states.
    Pecori Giraldi F; Pivonello R; Ambrogio AG; De Martino MC; De Martin M; Scacchi M; Colao A; Toja PM; Lombardi G; Cavagnini F
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):251-7. PubMed ID: 17223996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of prolactin secretion in patients with Cushing's disease. A comparative study on the effects of dexamethasone, lysine vasopressin and ACTH on prolactin secretion by the rat pituitary gland in vitro.
    Lamberts SW; de Quijada M; Visser TJ
    Neuroendocrinology; 1981 Mar; 32(3):150-4. PubMed ID: 6261178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypothalamic-pituitary function in Cushing's disease.
    Le Roith D; Shapiro MS; Gutman A; Spitz IM
    J Endocrinol Invest; 1979; 2(4):379-83. PubMed ID: 119799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.